Chimeric Therapeutics is trading 22.22% up now at A$0.01, but no clear company-specific catalyst has been verified for September 1, 2026.
- The August 19 trial update remains a major overhang: enrollment stopped after a second dose-limiting toxicity, and the company will not progress CHM-2101 in its current form.
- August 31 financial results reported an A$18.81 million net loss, offering no obvious bullish explanation.
- The move is best classified as an unconfirmed rebound in a highly volatile, low-priced biotech.